WO2005065309A3 - Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer - Google Patents

Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer Download PDF

Info

Publication number
WO2005065309A3
WO2005065309A3 PCT/US2004/043635 US2004043635W WO2005065309A3 WO 2005065309 A3 WO2005065309 A3 WO 2005065309A3 US 2004043635 W US2004043635 W US 2004043635W WO 2005065309 A3 WO2005065309 A3 WO 2005065309A3
Authority
WO
WIPO (PCT)
Prior art keywords
igfbp
mutated
native
cancer
treatment
Prior art date
Application number
PCT/US2004/043635
Other languages
French (fr)
Other versions
WO2005065309A2 (en
Inventor
Paul Toman
Original Assignee
Actis Biolog Inc
Paul Toman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actis Biolog Inc, Paul Toman filed Critical Actis Biolog Inc
Priority to JP2006547473A priority Critical patent/JP2007516727A/en
Publication of WO2005065309A2 publication Critical patent/WO2005065309A2/en
Publication of WO2005065309A3 publication Critical patent/WO2005065309A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Lentiviral delivery of native and mutated IGFBP-3 for treating cancer is described.
PCT/US2004/043635 2003-12-31 2004-12-29 Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer WO2005065309A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006547473A JP2007516727A (en) 2003-12-31 2004-12-29 Lentiviral vector delivery of native IGFBP-3 and mutant IGFBP-3 to treat cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53392103P 2003-12-31 2003-12-31
US60/533,921 2003-12-31

Publications (2)

Publication Number Publication Date
WO2005065309A2 WO2005065309A2 (en) 2005-07-21
WO2005065309A3 true WO2005065309A3 (en) 2005-12-29

Family

ID=34748980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/043635 WO2005065309A2 (en) 2003-12-31 2004-12-29 Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer

Country Status (3)

Country Link
JP (1) JP2007516727A (en)
CN (1) CN1980573A (en)
WO (1) WO2005065309A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153641B (en) * 2010-12-17 2013-06-12 浙江大学 Preparation method and application of mutain of human insulin-like growth factor binding protein 7 (IGFBP7)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562799B1 (en) * 1998-08-25 2003-05-13 The Johns Hopkins University School Of Medicine Stable hypoxia inducible factor-1α and method of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077291A1 (en) * 2000-09-22 2002-06-20 Alan Upshall Method of treatment of tumors using transforming growth factor-alpha
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
AU2001296846B2 (en) * 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562799B1 (en) * 1998-08-25 2003-05-13 The Johns Hopkins University School Of Medicine Stable hypoxia inducible factor-1α and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEVI ET AL: "Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo", PROSTATE, vol. 51, no. 2, May 2002 (2002-05-01), pages 141 - 152, XP002990377 *

Also Published As

Publication number Publication date
JP2007516727A (en) 2007-06-28
CN1980573A (en) 2007-06-13
WO2005065309A2 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MXPA02007099A (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging.
AU2003270280A1 (en) Use of native zein for improving the condition of hair, and corresponding agent
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
HK1162948A1 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer (hemiasterlin)
EP1503794A4 (en) Methods of treatement using ctla-4 antibodies
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
MXPA04003674A (en) Improved use of antitumoral compound in cancer therapy.
MXPA03008582A (en) Agents and methods for treatment of cancer.
WO2004104039A8 (en) Tumor antigens for prevention and/or treatment of cancer
AU2002318374A1 (en) Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway
GB0507598D0 (en) Composition
MXPA05011830A (en) Peptides for use in treating obesity.
WO2005065309A3 (en) Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2002340251A1 (en) Use of mx gtpases in the prognosis and treatment of cancer
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
AU7858601A (en) Treatment of part processed leather
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
AU2003250161A1 (en) Improvement in drums for the treatment of skins, hides and leather
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003280688A1 (en) Combination therapy of peptide vaccination and estramustine treatment
WO2001087039A3 (en) Treatment of neoplasia / transformation using pituitary tumor transforming gene 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006547473

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 200480042220.5

Country of ref document: CN

122 Ep: pct application non-entry in european phase